Nexgel, INC

NexGel, Inc. has entered into a new Executive Employment Agreement with CEO Adam Levy, detailing salary, bonus potential tied to EBITDA, and stock options.

NexGel, Inc. has postponed its 2026 Annual Meeting of Stockholders from July 10, 2026, to July 31, 2026, to allow more time for proxy solicitation.

NexGel, Inc. announced the resignation of director Scott Henry, effective July 1, 2026, citing a desire to reduce his workload and focus on other ventures.

NexGel, Inc. has released a new investor presentation dated June 2026, providing updated information to stakeholders.

NexGel, Inc. announced the appointment of Brian J. Kieser and Kevin Harris to its Board of Directors, coinciding with a strategic financing led by Sequence LifeScience.

NexGel, Inc. has appointed veteran financial leader Ian Blackman as Chief Financial Officer to oversee the integration of the Celularity acquisition and scale its healthcare and beauty portfolio.

NexGel reports Q1 2026 financial results, highlighting a net loss of $0.9 million and significant capital raising activities to support its Celularity biomaterials acquisition.

NexGel, Inc. reported increased revenue and improved net loss for the nine months ended September 30, 2025, but acknowledged substantial doubt about its ability to continue as a going concern and disclosed material weaknesses in internal controls.

NexGel, Inc. reported a significant revenue increase of over 100% for Q2 2025, alongside improved gross profit and reduced net loss, yet faces substantial doubt about its ability to continue as a going concern.

NexGel, Inc. saw a significant increase in revenue for the first quarter of 2025, driven by growth in contract manufacturing and branded products, but continues to operate at a loss.

NexGel, Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by its branded consumer products segment, including recent acquisitions.

NexGel, Inc. saw a 23.4% increase in revenue in the second quarter of 2024, primarily driven by growth in its branded consumer products segment.

NexGel, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding executive compensation, governance, and board composition.

NexGel, Inc. reported a 31.5% increase in net revenues to $11.421 million for the fiscal year ended December 31, 2025, driven by consumer product sales, but continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

NexGel, Inc. announces a substantial 112.5% increase in revenue for 2024, primarily driven by growth in branded consumer products and strategic acquisitions.

NexGel Inc. has filed an amendment to its 2023 annual report to include management's report on internal control over financial reporting, which was inadvertently omitted from the original filing.

NexGel Inc.'s 2023 annual report reveals significant revenue growth, strategic acquisitions, and ongoing development in medical devices and consumer products.

Adam R. Levy, Chief Executive Officer and a Director of Nexgel, Inc., received 160,000 shares of common stock on July 23, 2026.

NEXGEL, Inc. CEO Adam R. Levy reported the sale of 3,000 shares of common stock in an open market transaction.

NEXGEL, Inc. CEO Adam R. Levy reported the sale of 6,000 shares of common stock in open market transactions.

NEXGEL, Inc. CEO Adam R. Levy reported the sale of 2,000 shares of common stock in an open market transaction.

NEXGEL, Inc. CEO Adam R. Levy reported the sale of 13,000 shares of common stock in open market transactions.

Director Scott Robert Henry acquired a $25,000 convertible promissory note and associated warrants in NEXGEL, Inc.

NexGel, Inc. seeks stockholder approval for reincorporation to Nevada, a significant increase in authorized shares, and a discretionary reverse stock split.

NexGel, Inc. is seeking stockholder approval to increase its authorized common stock from 25 million to 1 billion shares to provide flexibility for future capital raises and strategic transactions.

NexGel's proxy statement details proposals for the annual stockholder meeting, including an amendment to the long-term incentive plan and director elections.

NexGel, Inc. will hold its 2024 Annual Meeting of Stockholders on June 17, 2024, to elect directors and ratify the appointment of its independent accounting firm.

NexGel, Inc. will hold its Annual Meeting of Stockholders on June 17, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Asymmetry Point LP, along with its General Partner Asymmetry Point Capital LLC and fund manager Aviv Argaman, has reported beneficial ownership of 745,000 shares of NexGel, Inc. common stock, representing 8.8% of the class.

Asymmetry Point LP, along with its general partner and fund manager, has disclosed a beneficial ownership of 7.49% of NexGel, Inc.'s common stock.